Submission to first decision (The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor)
Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date.
3 weeks
Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) 6 weeks
Submission to final decision (The average time from manuscript submission to the final editorial decision) 16 weeks
Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) 24 weeks

ACTA Pharmaceutica Sciencia 2026 , Vol 64 , Num 4
In silico exploration of Diospyros malabarica phytochemicals as multi-target therapeutics against prostate cancer: Network pharmacology, molecular docking and molecular dynamics simulation
Gana Manjusha KONDEPUDI 1 Aruna Kumari DOKKADA 1 Kanaka Raju ADDIPALLI 2
1 Vignan Institute of Pharmaceutical Technology, Department of Pharmacognosy, Visakhapatnam, India
2 Vignan Institute of Pharmaceutical Technology, Department of Pharmaceutical Chemistry, Visakhapatnam, India
DOI : 10.23893/1307-2080.APS64033 Viewed : 742 - Downloaded : 247 Prostate cancer remains a major cause of cancer-related mortality in men, underscoring the need for safer and more effective therapies. This study used an in silico approach to evaluate the anticancer potential of phytochemicals from Diospyros malabarica through integrated network pharmacology and molecular docking analyses. Thirty-six (36) reported phytochemicals were screened for pharmacokinetic and toxicity profiles using SwissADME, MolSoft, and ProTox-II. Five compounds—kaempferol, catechin hydrate, epicatechin, quercetin, and ascorbic acid—met favorable ADMET and drug-likeness criteria and were selected for further investigation. Network pharmacology identified 141 overlapping targets between these phytochemicals and prostate cancer-associated genes. Protein–protein interaction (PPI) network construction and enrichment analyses revealed eleven hub targets, including AKT1, EGFR, MMP9, BCL-2, SRC, ERBB2, ESR1, HIF1A, GSK3B, PTGS2, and FUT4. GO and KEGG analyses indicated significant enrichment in pathways such as HIF-1 signaling, PI3K–Akt signaling, EGFR inhibitor resistance, endocrine resistance, and prostate cancer signaling. Molecular docking revealed strong binding affinities of quercetin and kaempferol toward key oncogenic targets. FDA-approved drugs apalutamide, niraparib, dasatinib, and erlotinib showed comparable binding, validating the docking protocol. Molecular dynamics simulation further confirmed the stable interaction of quercetin with SRC, highlighting their potential as multitarget therapeutic candidates. Keywords : Diospyros malabarica, ADMET, network pharmacology, molecular docking, md simulation

Istanbul Medipol University